Código QR (código de barras bidimensional)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of...

ver descrição completa

Na minha lista:
Principais autores: Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2022-06-01
coleção:JTO Clinical and Research Reports
Assuntos:
Entrectinib
Intracranial efficacy
NSCLC
ROS1 fusions
Treatment post-crizotinib
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S266636432200056X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados